Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24424865 | 0.70 | KDM4E (0.46) | KDM4EALDH1A1POLBCYP11B2GRM5 | |
| SCHEMBL2297778 | 0.70 | KDM4E (0.46) | KDM4EALDH1A1POLBCYP11B2GRM5 | |
| SCHEMBL16321670 | 0.70 | ALDH1A1 (0.44) | KDM4EALDH1A1POLBCYP11B2GRM5 | |
| SCHEMBL30555131 | 0.68 | USP8 (0.35) | EGLN2 | |
| SCHEMBL24455466 | 0.68 | USP8 (0.35) | EGLN2 | |
| SCHEMBL22442090 | 0.67 | TDO2 (0.41) | KDM4EALDH1A1GRM5CYP1A2EGLN2 | |
| SCHEMBL31207517 | 0.67 | TDO2 (0.41) | KDM4EALDH1A1GRM5CYP1A2EGLN2 | |
| SCHEMBL14150472 | 0.67 | GABRG2 (0.48) | KDM4EALDH1A1POLBCYP11B2EGLN2 | |
| SCHEMBL25296164 | 0.66 | ALDH1A1 (0.50) | KDM4EALDH1A1POLBCYP11B2CYP1A2 | |
| SCHEMBL30510157 | 0.66 | ALDH1A1 (0.50) | KDM4EALDH1A1POLBCYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2025-05-01 | — | — | US | disclosed |
| CN-119504705-A | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114585614-B | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585614-A | Non-peptide somatostatin type 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885POLB 4524/4885 |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885POLB 4524/4885 |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885POLB 4524/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885POLB 4524/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | KDM4E 1542/4885ALDH1A1 4138/4885POLB 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.